Dr Jane Lowe Meisel speaks to ecancer about the results from the I-SPY2.2 trial which looked at rates of pathologic complete response after neoadjuvant datopotamab deruxtecan in neoadjuvant breast cancer.

The novel therapy was given as first in a sequence (Block A), followed by standard chemo/targeted therapies (Block B/C) if indicated.

Dr Meisel reports that datopotamab deruxtecan monotherapy was active, particularly in the HR-HER2- signature, but did not meet the pre-specified threshold for graduation.